Target Audience:

The internet broadcast will target gastroenterologists, nurses, NPs and PAs that care for patients with IBD.

Goal Statement:

The primary goal of this internet broadcast is to encourage the application of the latest advances in evidence-based medicine to improve the quality of care and improve outcomes for the patients affected by UC.

Educational Objectives:

Upon completion of this educational activity, participants should be able to:

  • Discuss key data regarding the latest diagnostic and treatment strategies for UC presented at DDW® 2020
  • Summarize implications of the current coronavirus pandemic on the management of patients with UC

Accreditation Statement and Credit Designation:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and GI Health Foundation. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Pfizer Inc.

Provided by

Accredited by

THURSDAY, SEPTEMBER 24, 2020

7:30 PM ET / 6:30 PM CT / 5:30 PM MT / 4:30 PM PT

FEATURED FACULTY

(SELECT A FACULTY MEMBER TO VIEW THEIR DISCLOSURES)

AGENDA
INTRODUCTION
IBD UPDATES FROM DDW® 2020
  • PATHOGENESIS AND EPIDEMIOLOGY FOR CLINICIANS
  • CLINICAL AND THERAPEUTIC ADVANCE
UPDATES ON THE MANAGEMENT OF ULCERATIVE COLITIS
UPDATES ON COVID-19 AND IBD
CONCLUSIONS

MARIA ABREU, MD

SPEAKER DISCLOSURES:

Speaker: Janssen, Prometheus Bioscience, Takeda, Focus Medical Communications, Boehringer Ingelheim Pharmaceuticals, Gilead, Imedex, Cornerstone Health, Inc, Landos Biophama, UCB Biopharma SRL, Eli Lilly, Cosmo Biopharma.

STEPHEN B. HANAUER, MD, FACG

SPEAKER DISCLOSURES:

Clinical Research: AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfier, Prometheus, Receptos, Takeda, UCB

Consultant: AbbVie, Allergan, Amgen, Arena, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Nestle, Novartis, Pfier, Progenity, Prometheus, Receptos, Salix,Samsung Bioepis, Seres Therapeutics, Takeda, Tigenex, UCB, VHsquared

DSMB: Arena, Bristol-Myers Squibb

Speaker: AbbVie, Janssen, Takeda

GARY LICHTENSTEIN, MD

SPEAKER DISCLOSURES:

Author (Honorarium): Up-To-Date

Book Royalty: SLACK, Inc

Consultant: Abbvie,CellCeutrix, Celgene, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Eli Lilly, American Regent, Merck, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals / Valeant, Shire Pharmaceuticals, Takeda, UCB

Consulting: Morphic Therapeutics

DSMB: Eli Lilly

Editor (Honorarium): (Gastro-Hep Communications), Springer Science and Business Media

Funding to University of PA (IBD Fellow Education): Janssen Orthobiotech, Pfizer Pharmaceuticals, Takeda

Honorarium (CME Program): American Regent, Merck, Romark

Honorarium for Associate Editor of American Journal of Gastroenterology: American College of Gastroenterology

Research: Celgene, Janssen Orthobiotech, UCB

Royalty for writing Textbook: "Clinical Management of Ulcerative Colitis": Professional Communications, Inc.